So this was originally a LGND internal project. I'd say it's too difficult a project for a small company like this with limited skills, so ideally I'd like to see them partner it if data looks at all promising. Can't say I've looked at it in detail - my interest has been in their thyroid beta agonist, which was originally out of Metabasis.
This paper (found by Miljenko) is what first re-engaged my interest in the company earlier this year:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.